Drug Screening in Gene-Fusion Cell Lines    

Background

The Role of Gene Fusion in Cancer

Gene fusion plays a crucial role in cancer development and treatment, representing a significant type of somatic mutation. Compared to point mutations, gene fusions more accurately reflect the genomic instability of tumors. Studies indicate that gene fusions are widely present across various cancer types, driving approximately 16.5% of cancer cases and serving as the sole driver in over 1% of cases. Around 6% of cases harbor actionable gene fusions.

Impact on Gene Expression

Gene fusion events are typically associated with altered expression of one or two fusion gene partners. Oncogenic genes tend to exhibit overexpression, while tumor suppressor genes may show reduced expression. For instance, fusion proteins involving oncogenes such as EGFR, ERBB2, or RET demonstrate increased expression of these genes. However, the expression patterns of most tumor suppressor genes vary inconsistently across different cancer types, generally trending towards reduced expression.

FDA-Approved Targeted Therapies

In clinical solid tumors, the FDA has approved multiple targeted therapies for treating gene fusions involving ALK, ROS1, RET, MET exon 14 skipping mutations, FGFR2, and NTRK1/2/3. The pathogenic mechanisms of gene fusion include dysregulation of gene transcription control and the production of functionally aberrant chimeric proteins, leading to inactivation of tumor suppressor genes and loss of protein function, thereby promoting cancer initiation and progression.

Figure 1. The figure describes how different types of gene fusions affect tumorigenesis and progression. (Lu B, et al., 2021)

Service Content

Gene-Fusion Cell Line Drug Screening Service

Creative Biogene's Gene Fusion Cell Line Drug Screening Service focuses on utilizing advanced gene editing technologies and diverse cell models to accurately simulate human disease conditions. Our services cover a wide range of disease models, including cancers, neurological disorders, immune modulation and inflammatory diseases, metabolic disorders, autoimmune diseases, hematologic disorders, liver diseases, kidney diseases, respiratory diseases, and more.
Our research primarily aims to evaluate drug efficacy in vivo, measuring key endpoints such as tumor growth inhibition, survival rates, and organ-specific responses. Our methodologies ensure data validity and practical evaluation within the systemic context to ensure the reliability and applicability of research findings.

Gene-Fusion Cell Line Drug Screening Service Process

• Initial Consultation and Project Planning
  Collaborative discussions to understand client goals and project requirements. Development of a customized project plan outlining the selection of gene fusion cell lines and assay methodologies.
• Cell Line Development and Validation
  Access to a validated library of diverse gene fusion cell lines or development of custom cell lines as per specific research needs. Rigorous validation ensures consistency with clinical relevance and genetic characteristics.
• Drug Screening and Assay Execution
  They implement high throughput screening assays to evaluate candidate drugs against gene fusion cell lines. Detailed assays measure efficacy, resistance profiles, and therapeutic response parameters.
• Data Analysis and Interpretation
  Utilization of advanced bioinformatics tools for comprehensive data analysis. Generation of detailed reports with actionable insights to guide further research and development strategies.
• Continuous Support and Collaboration
  Ongoing support throughout the project duration, including consultation on data interpretation and future research directions. A collaborative approach to ensure project success and achievement of research milestones.

Feature

Gene-Fusion Cell Line Drug Screening Service Features

• Establishment of Gene Fusion Cell Models: Using advanced gene editing tools like CRISPR/Cas9, we precisely engineer gene fusion cell lines that accurately replicate human disease conditions. Our extensive cell line repository ensures a diverse selection, and we offer custom design services if specific cell lines are not readily available.
• Drug Potency Assessment: Conducting comprehensive in vivo studies to assess drug pharmacokinetics, pharmacodynamics, and therapeutic potential. These studies provide detailed insights essential for advancing new drug development strategies.
• Integrated Data Analysis: Employing state-of-the-art imaging technologies and multidimensional data analysis methods to provide clients with a profound understanding of drug mechanisms and effects. This integrated approach accelerates the drug development process.

Contact Us

Enhance your drug discovery initiatives with Creative Biogene's Gene Fusion Cell Line Drug Screening Service. Our specialized expertise in evaluating targeted therapies against gene fusion-driven diseases ensures precise and impactful results. Contact us today to discuss your project requirements and explore how we can support your research objectives effectively.